Matters arising

The G protein preference of orexin receptors is currently an unresolved issue

Received: 2 August 2022	Jyrki P. Kukkonen 🕲 ¹ 🖂
Accepted: 15 May 2023	
Published online: 01 June 2023	ARISING FROM J. Yin et al. Nature Communications https://doi.org/10.1038/s41467-022-30601-3 (2022)
Check for updates	

Orexin receptors (OX₁ receptor and OX₂ receptor) are G proteincoupled receptors. A recent study by Yin et al.¹ was based on the prior proposal that OX₂ receptor would couple much more strongly to G_q than G_i family proteins. The complexes of the agonist-bound OX₂ receptor with G_q mimetic or G_i were visualized by cryo-electron microscopy, and the observed differences in the interactions between the receptor and the G proteins were proposed to constitute the structural basis for the weaker coupling to G_i . However, there is no unequivocal support for this preference in the literature and the findings of this study¹ may depend on the experimental setup and not reflect physiological G protein coupling of OX₂R.

The study of Yin et al. supplied structural information on G protein interaction of the agonist-bound OX_2 receptor¹. For instance, conformation of both the receptor and the agonist in complex were seen to adapt to different G proteins, in this case a G_a mimetic or G_i. However, the interaction of the chimeric G proteinsas used here for G_q-with the receptors is not necessarily the same as that of native ones². Yin et al.¹ additionally investigated OX_2 receptor signaling upon heterologous expression together with $G_{\alpha\alpha}$ or $G_{\alpha i1}$ (for separate assays) in HEK293 cells. They observed inositol phosphate (IP) accumulation but only weak decrease in forskolinelevated cAMP levels (low maximum response, EC50-values shifted 50-600-fold; Fig 5cd) upon stimulation with the agonists orexin-B and TAK-925. This was taken to indicate preferential activation of G_a, and the structural differences between the receptor interaction with the proteins mimicking Gq and Gi were interpreted in the light of this conclusion.

Orexin receptors are promiscuous receptors. The sum of the studies of their G protein preference is inconclusive due to their limited number, exclusive use of one agonist (orexin-A) and variation between the experimental conditions and assays used. Coupling of the endogenous OX_2 receptor in the adrenal cortex and of the mixed receptor population in the hypothalamus to $G_{i/o}$, G_s and G_q families of G proteins, as well as coupling of the OX_1 receptor-dominant mixed population to $G_{i/o}$ in the brain stem has been shown using radioactive methods (³³P-GTP azidoanilide and ³⁵S-GTP γ S labeling)³. In recombinant CHO-K1 cells, the results indicate coupling of both receptors to the putative G_i and G_q responses

with largely the same potency⁴⁻⁶. In contrast, based on a study with recombinant BIM cells, suggesting that both receptors couple to a pertussis toxin-insensitive Ca^{2+} elevation while OX_2 receptor also couples to a pertussis toxin-sensitive cAMP decrease, it is often inferred that only OX_2 receptor couples to G_i^7 .Interestingly, orexin-A is >1000-fold less potent for the putative G_q than G_i response⁷. In recombinant HEK293 cells, G_q , G_i and G_s coimmunoprecipitate with OX_1 receptor⁸. Using chimeric G proteins, both receptor subtypes seem to activate all G protein subfamilies except $G_{12/13}^9$. The coupling to $G_{11,3}$ and G_q is equipotent (EC₅₀ = 25 and 13 nM, respectively; https://gproteindb.org/signprot/couplings). In yet another study, activated OX_2 receptors are shown to couple to all G protein subfamilies except G_s ; the EC₅₀ value is 5-fold lower for G_q than $G_{i/o}^{10}$ (https://gproteindb.org/signprot/couplings).

The picture thus varies a lot from study to study, and all experimental approaches have their limitations. However, we can confidently state that there is no definitive evidence that the $G_{i/o}$ -coupling of OX₁ and OX₂ receptors would be weaker than their G_q -coupling for orexin-A, while other agonists have not been investigated. Yin et al.¹ largely miss this literature, which results in a misleading statement: "Several studies of OX₂ receptor(...) have indicated that it can also stimulate G_s and G_i signaling, although with reduced orexin potency^{7,9}." While several studies (but not all) find the G_s -coupling to G_i than G_q and the cited ones do not; the former suggests much more potent coupling to G_i than G_q while the latter shows an insignificant difference. For orexin-B and TAK 925, Yin et al.¹ observed much weaker coupling to cAMP decrease than IP elevation. There are potential explanations to this finding:

- (1) Multiple factors including $G_{\alpha i}$, $G_{\alpha s}$, $G_{\beta \gamma}$, Ca^{2+} and phosphorylation regulate the 9 membrane-bound adenylyl cyclase (AC) isoforms, each in a different way¹¹. The inputs interact negatively or positively, often even synergistically or by gating one another.
- (2) Orexin receptors can couple to multiple G proteins (and other pathways), which can give rise to several signals to AC: e.g., G_q to Ca^{2+} or protein kinase C (PKC); G_i to $G_{\alpha i}$; G_s to $G_{\alpha s}$; in addition, all G proteins could give rise to $G_{\beta \gamma}$ signaling. For OX_1

¹Department of Pharmacology, Institute of Biomedicine, Faculty of Medicine, University of Helsinki, POB 63, FI-00014 Helsinki, Finland. © e-mail: jyrki.kukkonen@helsinki.fi

receptor, we could observe G_i -, G_s - and PKC signaling to AC (likely via G_q), and there were differences in OX₁R-mediated signaling as compared to other, in principle similar factors⁴.

(3) Cellular cAMP levels are not only regulated by ACs but also by cyclic nucleotide phosphodiesterases (PDEs)¹². When AC regulation is investigated, it is necessary to block the PDE activity since (a) it may be difficult to see any cAMP elevation in the presence of efficient PDE activity (e.g., Fig. 9A, in ref. 13) and (b) the receptor under investigation may also regulate PDEs via multiple potential factors^{11,12}.

Due to this high level of complexity, when investigating cAMP signals, one needs to carefully identify all potential players and study these in isolation⁴. When this is not done, the risk for erroneous conclusions is high. The experimental setup utilized by Yin et al.¹ seems to not account for the points above; the AC regulation in this cellular background and the potential orexin receptor-triggered signals were not mapped and no PDE inhibitor was used. This means that the cAMP results¹ cannot currently be taken for G_i and that the results reported by Yin et al.¹ are not definitive and need to be interpreted carefully.

The proposal that orexin receptors are G_q-coupled largely arises from extrapolation of the original Sakurai et al. paper¹⁴ and other papers suggesting strong coupling of the receptors to Ca²⁺ elevation (and sometimes to phospholipase C (PLC) activation)^{3,15}. While this is not unreasonable, the evidence provided was obtained in recombinant, orexin receptor-overexpressing cells. Very little has been done to assess the molecular details of orexin receptor signaling in CNS neurons, their major target, and most studies do not identify signaling components between the receptors and the "targets" (e.g., ion channels)^{3,15}. There is little direct evidence for G_q coupling in the CNS neurons. Very few studies measure Ca²⁺ release. A few more directly or indirectly indicate Ca²⁺ elevation upon orexin receptor activation, but there is nothing pointing at the G_q-PLC axis. It is important to underline that "Ca²⁺ release" specifically means Ca2+ flux into the cytosol from intracellular stores while "Ca²⁺ elevation" incorporates both release and influx, the latter of which does not necessarily suggest involvement of G_q. A few studies report an inhibition of the orexin response with PKC inhibitors³. Thus, the statement by Yin et al.¹ "These results bolster observations that orexins function mainly by stimulating calcium release through activating Gq^{3,14}" is inaccurate and misleading. We definitely do not take that stand in our review³.

In conclusion, while the G_q signaling seems dominant in many experimental scenarios^{5,6}, we have no proof that this is the case physiologically. Studies such as Yin et al.¹ provide valuable information on the structural basis of the receptors' interactions with G proteins, and similar rigor is needed when the interactions are assessed functionally. Further studies of orexin-B (and synthetic agonists) signaling will contribute to the assessment of potential biased signaling.

Data availability

Not relevant: there is no new data and no new analyses based on the data. All previous data are available in the publication itself and in its references.

References

- 1. Yin, J. et al. Molecular mechanism of the wake-promoting agent TAK-925. *Nat. Commun.* **13**, 2902 (2022).
- Kostenis, E., Waelbroeck, M. & Milligan, G. Techniques: promiscuous Galpha proteins in basic research and drug discovery. *Trends Pharm. Sci.* 26, 595–602 (2005).
- Kukkonen, J. P. & Leonard, C. S. Orexin/hypocretin receptor signalling cascades. Br. J. Pharm. 171, 294–313 (2014).

- 4. Holmqvist, T. et al. OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms. *J. Biol. Chem.* **280**, 6570–6579 (2005).
- Kukkonen, J. P. OX orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells. *Cell Signal.* 28, 51–60 (2016).
- 6. Kukkonen, J. P. G-protein-dependency of orexin/hypocretin receptor signalling in recombinant Chinese hamster ovary cells. *Biochem. Biophys. Res. Commun.* **476**, 379–385 (2016).
- Zhu, Y. et al. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J. Pharm. Sci. 92, 259–266 (2003).
- Magga, J. et al. Agonist potency differentiates G protein activation and Ca2+ signalling by the orexin receptor type 1. *Biochem. Pharm.* 71, 827–836 (2006).
- 9. Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs. *Cell* **177**, 1933–1947.e25 (2019).
- 10. Avet, C. et al. Effector membrane translocation biosensors reveal G protein and betaarrestin coupling profiles of 100 therapeutically relevant GPCRs. *Elife* **11**, e74101 (2022).
- Halls, M. L. & Cooper, D. M. F. Adenylyl cyclase signalling complexes—pharmacological challenges and opportunities. *Pharm. Ther.* **172**, 171–180 (2017).
- Bender, A. T. & Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. *Pharm. Rev.* 58, 488–520 (2006).
- Ammoun, S. et al. OX1 orexin receptors activate extracellular signalregulated kinase (ERK) in CHO cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling. *Mol. Endocrinol.* 20, 80–99 (2006).
- 14. Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* **92**, 573–585 (1998).
- Leonard, C. S. & Kukkonen, J. P. Orexin/hypocretin receptor signalling: a functional perspective. *Br. J. Pharm.* **171**, 294–313 (2014).

Acknowledgements

J.P.K.'s research is supported by the Magnus Ehrnrooth Foundation, the Liv & Hälsa Foundation and Finska Läkaresällskapet.

Author contributions

J.P.K. analyzed the literature and wrote the manuscript.

Competing interests

The author has received a one-time honorarium from Idorsia Pharmaceuticals Ltd for participation in the symposium Orexin Science Summit in Oct 20–22 2021 and writing a review on orexin signaling in The Orexin System. Basic Science and Role in Sleep Pathology (https://doi.org/10. 1159/isbn.978-3-318-06844-3).

Additional information

Correspondence and requests for materials should be addressed to Jyrki P. Kukkonen.

Peer review information *Nature Communications* thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/.

© The Author(s) 2023